The novel oral Syk inhibitor, Bl1002494, protects mice from arterial thrombosis and thromboinflammatory brain infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 6, 2016, Pages 1247-1253

  Van Eeuwijk, Judith M M ^a,b   Stegner, David ^a,b   Lamb, David J ^c   Kraft, Peter ^a   Beck, Sarah ^a,b   Thielmann, Ina ^a,b   Kiefer, Friedemann ^d   Walzog, Barbara ^e   Stoll, Guido ^a   Nieswandt, Bernhard ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

mice; platelets; stroke; Syk kinase; thrombosis

Indexed keywords

BI 1002494; COLLAGEN RECEPTOR; ENZYME INHIBITOR; GLYCOPROTEIN VI; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; UNCLASSIFIED DRUG; FIBRINOLYTIC AGENT; PROTEIN KINASE INHIBITOR; SYK PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG SAFETY; DRUG SELECTIVITY; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIAL OCCLUSIVE DISEASES; BLOOD; BRAIN; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; INFARCTION, MIDDLE CEREBRAL ARTERY; KNOCKOUT MOUSE; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHENOTYPE; THROMBOSIS; TIME FACTOR;

ADMINISTRATION, ORAL; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BLOOD PLATELETS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; GENOTYPE; HEMOSTASIS; INFARCTION, MIDDLE CEREBRAL ARTERY; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENOTYPE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SYK KINASE; THROMBOSIS; TIME FACTORS;

EID: 84964289045     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306883     Document Type: Article

References (27)

1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 44 870 947. doi: 10.1161/STR.0b013e318284056a
2. Berkhemer OA, Fransen PS, Beumer D, MR CLEAN Investigators A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015 372 11 20. doi: 10.1056/NEJMoa1411587
3. Soares BP, Tong E, Hom J, Cheng SC, Bredno J, Boussel L, Smith WS, Wintermark M, Reperfusion is a more accurate predictor of follow-up infarct volume than recanalization: a proof of concept using CT in acute ischemic stroke patients. Stroke 2010 41 e34 e40. doi: 10.1161/STROKEAHA.109.568766
4. Zinkstok SM, Beenen LF, Majoie CB, Marquering HA, de Haan RJ, Roos YB, Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial. Stroke 2014 45 3080 3082. doi: 10.1161/STROKEAHA.114.006268
5. Stegner D, Haining EJ, Nieswandt B, Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway. Arterioscler Thromb Vasc Biol 2014 34 1615 1620. doi: 10.1161/ATVBAHA.114.303408
6. Séverin S, Pollitt AY, Navarro-Nuñez L, Nash CA, Mourão-Sá D, Eble JA, Senis YA, Watson SP, Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem 2011 286 4107 4116. doi: 10.1074/jbc.M110.167502
7. Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010 115 2578 2585. doi: 10.1182/blood-2009-08-236471
8. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008 58 3309 3318. doi: 10.1002/art.23992
9. Braselmann S, Taylor V, Zhao H, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006 319 998 1008. doi: 10.1124/jpet.106.109058
10. Clemens GR, Schroeder RE, Magness SH, Weaver EV, Lech JW, Taylor VC, Masuda ES, Baluom M, Grossbard EB, Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 2009 85 130 136. doi: 10.1002/bdra.20505
11. Currie KS, Kropf JE, Lee T, Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem 2014 57 3856 3873. doi: 10.1021/jm500228a
12. Thoma G, Smith AB, van Eis MJ, Vangrevelinghe E, Blanz J, Aichholz R, Littlewood-Evans A, Lee CC, Liu H, Zerwes HG, Discovery and profiling of a selective and efficacious Syk inhibitor. J Med Chem 2015 58 1950 1963. doi: 10.1021/jm5018863
13. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C, An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 2015 125 2336 2343. doi: 10.1182/blood-2014-08-595934
14. Meltzer EO, Berkowitz RB, Grossbard EB, An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005 115 791 796. doi: 10.1016/j.jaci.2005.01.040
15. Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, McKenzie SE, PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 2011 117 2241 2246. doi: 10.1182/blood-2010-03-274969
16. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB, Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009 113 3154 3160. doi: 10.1182/blood-2008-07-166439
17. Poole A, Gibbins JM, Turner M, van Vugt MJ, Van De Winkel JG, Saito T, Tybulewicz VL, Watson SP, The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997 16 2333 2341. doi: 10.1093/emboj/16.9.2333
18. Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, Finney BA, Vögtle T, Remer K, Braun A, Bösl M, Watson SP, Nieswandt B, Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 2013 33 926 934. doi: 10.1161/ATVBAHA.112.300672
19. Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, Shattil SJ, Ginsberg MH, Tybulewicz VL, Phillips DR, Genetic and pharmacological analyses of Syk function in alphaIIbbeta3 signaling in platelets. Blood 1999 93 2645 2652
20. Lamb DJ, Wollin SL, Schnapp A, Bi 1002494, a novel potent and selective oral syk inhibitor displays differential potency in human basophils and b-cells [published online ahead of print April 5, 2016]. J Pharmacol Exp Ther. doi: 10.1124/jpet.116.233155. http://jpet.aspetjournals.org/content/early/2016/04/05/jpet.116.233155.long
21. Hess PR, Rawnsley DR, Jakus Z, Yang Y, Sweet DT, Fu J, Herzog B, Lu M, Nieswandt B, Oliver G, Makinen T, Xia L, Kahn ML, Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. J Clin Invest 2014 124 273 284. doi: 10.1172/JCI70422
22. Andre P, Morooka T, Sim D, Critical role for Syk in responses to vascular injury. Blood 2011 118 5000 5010. doi: 10.1182/blood-2011-06-360743
23. Asazuma N, Wilde JI, Berlanga O, Leduc M, Leo A, Schweighoffer E, Tybulewicz V, Bon C, Liu SK, McGlade CJ, Schraven B, Watson SP, Interaction of linker for activation of T cells with multiple adapter proteins in platelets activated by the glycoprotein VI-selective ligand, convulxin. J Biol Chem 2000 275 33427 33434. doi: 10.1074/jbc.M001439200
24. Abtahian F, Guerriero A, Sebzda E, Lu MM, Zhou R, Mocsai A, Myers EE, Huang B, Jackson DG, Ferrari VA, Tybulewicz V, Lowell CA, Lepore JJ, Koretzky GA, Kahn ML, Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003 299 247 251. doi: 10.1126/science.1079477
25. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T, The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils. Mol Cell Biol 1998 18 4209 4220
26. Finney BA, Schweighoffer E, Navarro-Núñez L, CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood 2012 119 1747 1756. doi: 10.1182/blood-2011-09-380709
27. Herzog BH, Fu J, Wilson SJ, Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 2013 502 105 109. doi: 10.1038/nature12501